Persisting dilemmas
nephrological community into believers and skeptics, [10] : [110] [111] [112] [113] [114] [115] [116] and even opponents, of either concept. It will focus on the 'mathematical philosophy' of survival analysis from a clinical point of view, and will interval. This also implies that deviation from reality is greatest in the longest survival times, as fewer discuss how statistical techniques can influence the outlook of the results. The reasons that the final patients are then present on whom the estimations are based. Kaplan-Meyer and life- In a Cox-regression model, corrections can be made statistical methods, since not all patients considered for different comorbidity factors. The Cox's model will have died at the end of the observation period. In assumes that independent variables are related to surthese patients, the total time of survival is not known. vival time by a multiplicative effect on the hazard Therefore, the data of these patients cannot be entered function H0(t), the latter being the underlying 'basic' in 'classic' statistical methods [4] . For example, if a hazard equal to all participants. Unfortunately, H0(t) patient is started on PD 36 months before the end of is unknown, and only the relative risk, being the ratio the observation period, all one can say is that the of the hazards of two different subjects, can be calcupatient lived longer than 36 months, but no data on lated. This number is then the relative risk for subject the real survival are available. For these patients it is 1 compared to subject 2. It should be emphasized that said that the information is 'censored', as they did not curves that result from a Cox regression analysis are reach the final outcome point. Survival data analysis only reflecting 'predictive calculations' rather than the techniques such as Kaplan-Meier or Cox regression real situation. Results can, for example, be presented were developed to analyse this type of 'censored' with all comorbidity factors entered as absent, and the information, and these techniques account for the 'loss resulting curve will show seemingly better results comof information' due to censoring. It is easy to under-pared to a curve where comorbid conditions are taken stand that the results become less reliable as the ratio at the mean (Figure 1 ). This is an example of presentaof 'censored/uncensored cases' increases, as the fate of tion bias, and when comparing results of different the uncensored cases heavily influences the final verdict. centres, one should be aware of this. Consequently, the 'event numbers' (i.e. the real number of patients at risk at a certain moment on which the
Standardized mortality ratios and Poisson analysis
analysis is based) should always be provided in survival curves. Also the reason why a patient was censored is of importance. If the reason for censoring is not related Another method to analyse survival data is the use of to the treatment that is analysed, then this censoring mortality rates [5] . The 'standardized mortality ratio' is called 'not-informative'. This occurs for example (SMR) is the ratio of the total observed mortality in when a patient is censored because the observation of the investigated (treatment) group to the total number the study ended before he/she died, or when the patient of expected deaths in a group of patients. An SMR of is lost for follow up because he/she moved to another >1 indicates higher than expected mortality, while an city. However, if a patient is lost to follow-up because SMR <1 indicates lower than expected survival. A of non-compliance, then a relationship between the potential pitfall here is that the SMR itself is prone to treatment and the reason for non-compliance can random variation. Therefore, also confidence intervals possibly exist. In this case, censoring is called 'inform-(CI, mostly 95%CI ) of the SMR have to be provided. ative', and such censoring is in principle not allowed. The probability that the real value of the SMR will be Such a patient has to be withdrawn from the analysis, in this confidence interval is 95%. Another problem is or at least a separate analysis of this type of patient has to be performed. The core of the method is the fact that the survival prevalent vs incident patient inclusion function S(t), being the probability to be alive at a the total number of patients 'N' who entered that that the SMRs have to be calculated using the reference included as 'incident', i.e. starting new on ESRD treatment, or as 'prevalent', i.e. patients who have for a specific group of patients, as the expected mortality also depends on patient characteristics such as age, been some time on ESRD treatment. In the latter case, patients who start RRT and die during the inclusion race, sex, diabetes, cardiovascular disease, or other comorbid conditions. Therefore, SMR analysis is par-window are excluded from the study. Thus this analysis favours the method with the highest initial mortality. ticularly useful for analyses of large patient groups, comparing one treatment group with another, or one The use of incident or prevalent patients can give markedly different results, as was shown by Vonesh centre with another.
Poisson analysis is another method for the calcula-and Moran [6 ] . tion and comparison of adjusted survival rates.
Variables denoting the number of events in a certain

Clinical relevance
unit of time are distributed according to the Poisson distribution. It is assumed that the events occur randomly, independently of one another and with an Another crucial point is the definition of what is being average rate that remains unchanged over the observa-analysed. This largely determines the clinical relevance tion period. For survival analysis, one can consider the of the analysis. It is important to consider the period number of patients at risk, multiply this with the days of time that is defined as 'survival time'. In the first the patients were 'at risk' on the treatment, and divide modality survival analysis, survival time is considered this by the number of observed deaths. This results in as time on the initial RRT modality. Only death is a 'mortality rate'. This mortality ratio can also be seen, considered as a final event, and patients are censored just as in Cox regression analysis, as the composite at transfer to another dialysis modality, at transplantaregression of the influence of different risk factors, thus tion, loss of follow-up, or at the end of observation. allowing for adjustment for comorbid conditions. The
The intention-to-treat survival analysis considers the mortality ratio can then be compared with another sum of the time on HD and the time on PD. In this population, or with a reference population. It is of analysis death is considered as the final event, and note that, unlike with Cox regression, the use of patients are censored at the moment of transplantation, Poisson analysis assumes that the form of the under-at loss of follow-up or at the end of the observation, lying risk distribution is known and constant during but they are not censored at transfer from PD to HD the observed period. As the hazard function of mortal-or vice versa. ity in a dialysis patient is not constant over time, this
The previous two analyses only consider the time premise means that Poisson analysis for survival in on renal replacement, and exclude the time after trans-ESRD is only robust for observations made over plantation. These analyses are thus applicable for all shorter time periods.
patients, whether they are on the waiting list for transplantation or not. For the patients not on the waiting list, the intention-to-treat analysis gives their Incident vs prevalent patient inclusion life expectancy. For patients on the waiting list, it shows their probability to survive until a renal graft becomes available. It is quite acceptable that patients One should also pay attention to the manner in which patients are included in the study. Patients can be on the waiting list for transplantation will in general be in a better condition, compared to those not on the can have an important impact on outcome.
Furthermore, an adequate quantification of the severity waiting list, which could be a possible confounding of comorbid conditions is also often difficult. factor. This may explain, at least in part, the difference Congestive heart failure or diabetes mellitus are very in survival on RRT between Europe and Japan, as in difficult to grade; for example, in most studies a patient Europe, the 'fittest' patients drop out from the analysis with 3 years of diabetes is given the same risk as a at transplantation, leaving for further analysis only the patient with 20 years of diabetes, while the conpatients with contraindications for transplantation.
sequences of the disease will be greatly different. This may also be a confounding factor in the analysis Mortality comparisons should thus be viewed with between PD and HD.
caution regarding the inclusion of comorbid conditions In the total survival analysis, survival time is considand the way their severity is scored. On the other ered as the total time on PD, on HD, and after hand, one should avoid correcting for factors that transplantation. Death is considered as the final event probably do not affect outcome in the observed time and patients are only censored at the end of span, as this complicates the analysis and potentially observation.
increases random noise. Care should also be taken to Technique success is defined as the probability of correct for risk factors that are related to the treatment having a patient alive on his initial modality. Death under consideration. Nutritional status for example and change of modality are considered as final events, might be a factor related to adequacy, so this covariate and patients are censored at the time of transplantation should not be corrected for in a prevalent patient or at the end of follow-up. Another way of looking at analysis, as malnutrition may be the consequence of 'technique survival' is to censor patients at their death, the treatment. In an incident approach, however, it the underlying reasoning being that death is not the might be included, as in this case it is a marker of cause of technique failure, and that technique survival nutritional status before dialysis treatment was started. would have been longer if the patient had not died. In
Another important point should be made concerning this analysis, only real 'technique failures' are considthe exact meaning of relative risks. Relative risks can, ered as end-points. It is clear that the results of this from a clinical point of view, only be interpreted if type of analysis are far more 'flattering' compared to also the real mortality risk is known. If the relative those where death is also considered as technique mortality risk of group A to group B is 2, this means failure.
that with a real mortality risk in group B of 1/10 000, Most earlier survival analyses of ESRD patients in group A it will be 2/10 000. This can be a statistically used the first modality survival approach [7, 8] . In our significant difference, but from a clinical point of view opinion, this 'survival' does not correspond with the it is often meaningless. clinical reality, as most ESRD patients are treated
It is also of note that studies with a low number of successively with different treatment modalities. Total patients are prone to false negative results (no statisticsurvival time and intention-to-treat modality survival ally significant difference noted, whilst in reality there are of greater interest for the individual patient [3] . It is one), and that in studies with large patient numbers, is gratifying to see that the most recent papers on this false positive results can emerge (statistically significant topic used 'intention-to-treat' analysis [9] . However, difference without clinical meaning). to our knowledge, none of these papers has separately
In conclusion, the interpretation of papers analysing analysed the outcomes of patients transferred from survival comparisons should be done with attention to one modality to another, thereby neglecting the poten-the methodological biases, and their implications, realtial importance of the sequence and timing of the izing, however, that a 'perfect' comparison in a difficult different RRT modalities.
field such as RRT is nearly impossible. Another important confounding factor in survival analysis is, of course, the quality of the delivered care. Although this is difficult to measure, the experience with a technique can be estimated by the percentage of patients being treated on that modality. In this References regard, it is striking that in the study by Bloembergen the patients were treated with PD. 
